Biotech's ESA Burden Lifted? 'Harm' Rule Ends in 60 Days, Easing Facility Permits
The rescission of the ESA's 'harm' definition removes a major regulatory hurdle for biotech and pharma facility construction near sensitive habitats. Starting September 12, 2026, indirect habitat impacts will no longer trigger 'take' liability, potentially accelerating project timelines and reducing permitting costs for life-science companies.